BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Wolf Bites Woman in Shocking Attack at Busy Shopping Center - 2'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- 3OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- 4Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- 5A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Best Wellness Tracker Keep You On target
- Overhaul Your Rest: Tips for a Serene Evening
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- 12 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- 15 skywatching events you won't want to miss in 2026
- Top German court to rule on claims by Wirecard shareholders
- Opening Achievement: 8 Methodologies for Compelling Using time productively
- Truly amazing Palaces: Which Is Your Number one?
